“Lebrikizumab Provides Rapid Response in EASI Components and Itch in Moderate-to-Severe Atopic Dermatitis”. SKIN The Journal of Cutaneous Medicine 7, no. 6 (November 13, 2023): s279. Accessed May 1, 2026. https://skin.dermsquared.com/skin/article/view/2389.